Market Insight - The war on superbugs
This article was originally published in Scrip
Executive Summary
Since the development of the first antibiotics, resistant strains of bacteria, in particular Staphylococcus aureus, have increasingly become an obstacle to the successful use of such drugs. When penicillin was first introduced in 1943, resistant S aureus infections were almost unheard of yet, just four years later, a resistant strain was identified. By 1950, around 40% of nosocomial S aureus infections were penicillin-resistant, and this figure rose to around 80% by 1960. Penicillin resistance in S aureus is mediated by β-lactamase. This enzyme is produced by the bacterium and it hydrolyses the β-lactam ring of the penicillin structure, rendering it inactive.
You may also be interested in...
2011 Scrip Asia 100 - Abbott bullish about India but must work hard to retain crown
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
2011 Scrip Asia 100 - Asia life science-focused VC firms
Asia life science-focused VC firms*
2011 Scrip 100: Re-engineering Roche
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.